Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial

Stem Cell Research & Therapy

Li Huang¹  Ziliang Tu¹  Dabin Wang¹  Zegan Liu¹  Hengdong Wang¹  Ruibo Zhang¹  Yong Wang¹  Zhousheng Xiao²  Che Zhang³  Li Liu³  Xihui Zhou³  Jiaowei Gu³  Xiang Hu⁴  Zunchen Ke⁵ 

[1]Affiliated Taihe Hospital of Hubei University of Medicine

[2]Department of Medicine, University of Tennessee Health Science Center

[3]Department of Neonatology, The First Affiliated Hospital of Xi’an Jiaotong University

[4]Shenzhen Beike Biotechnology Co., Ltd

[5]Shiyan City Disabled Persons’ Federation

关键词: Mesenchymal stem cells;    Umbilical cord;    Cerebral palsy;    Clinical trial;    Cell transplantation;    Activities of daily living;   

DOI  :  10.1186/s13287-019-1545-x

来源: DOAJ

【 摘 要 】

Abstract Background Cerebral palsy (CP) is a syndrome of childhood movement and posture disorders. Clinical evidence is still limited and sometimes inconclusive about the benefits of human umbilical cord mesenchymal stem cells (hUC-MSCs) for CP. We conducted a randomized trial to evaluate the safety and efficacy of hUC-MSC transplantation concomitant with rehabilitation in patients with CP. Methods Eligible patients were allocated into the hUC-MSC group and control group. In addition to rehabilitation, the patients in the hUC-MSC group received four transfusions of hUC-MSCs intravenously, while the control group received a placebo. Adverse events (AEs) were collected for safety evaluation in the 12-month follow-up phase. Primary endpoints were assessed as activities of daily living (ADL), comprehensive function assessment (CFA), and gross motor function measure (GMFM) scales. In addition, cerebral metabolic activity was detected by 18F-FDG-PET/CT to explore the possible mechanism of the therapeutic effects. Primary endpoint data were analyzed by ANOVA using SPSS version 20.0. Results Forty patients were enrolled, and 1 patient withdrew informed consent. Therefore, 39 patients received treatments and completed the scheduled assessments. No significant difference was shown between the 2 groups in AE incidence. Additionally, significant improvements in ADL, CFA, and GMFM were observed in the hUC-MSC group compared with the control group. In addition, the standard uptake value of 18F-FDG was markedly increased in 3 out of 5 patients from the hUC-MSC group at 12 months after transplantation. Conclusions Our clinical data showed that hUC-MSC transplantation was safe and effective at improving the gross motor and comprehensive function of children with CP when combined with rehabilitation. Recovery of cerebral metabolic activity might play an essential role in the improvements in brain function in patients with CP. The therapeutic window, transfusion route, and dosage in our study were considerable for reference in clinical application. Trial registration Chictr.org.cn, ChiCTR1800016554. Registered 08 June 2018—retrospectively registered. The public title was “Randomized trial of umbilical cord-derived mesenchymal stem cells for cerebral palsy.”

【 授权许可】

Unknown